Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion in Cash Deal

Johnson & Johnson has agreed to acquire Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. Halda is a clinical-stage biotechnology company with a platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. The acquisition strengthens Johnson & Johnson's oncology pipeline and is expected to close within a few months.